Podcasts about Prostate cancer

Is what I've been doing for years helpful for achieving autophagy?When you say low carb, do you mean low complex carb or low simple and processed carb?What daily multivitamin would you recommend for a male age 50 plus?Which supplement should I take for elevated triglycerides?

Integrative Healthcare Symposium highlightsWhat supplements can help combat the side effects of cancer therapy?Will my son's use of Zepbound affect his fertility?

What do you do when doctors tell you that you have two to three months to live? In this powerful episode of Integrative Cancer Solutions, Dr. K sits down with stage 4 prostate cancer survivor Chuck Keels, who was diagnosed with terminal cancer that had spread to 90% of his bones. Placed in hospice care and given morphine to manage the pain, Chuck was told there was nothing more that could be done. But what followed was nothing short of extraordinary. Chuck shares his journey through chemotherapy, radical surgery, juicing, natural therapies like soursop and frankincense, movement after spinal fractures, and a radical shift in mindset. He opens up about faith, the mind-body connection, psycho-neuro-immunology, and the moment he believes divine intervention changed everything. Today, cancer-free, Chuck is the founder of Living Hope Cancer Foundation, helping patients find support, navigation, and hope after diagnosis. If you or someone you love has received a cancer diagnosis, this conversation could change everything. Key Takeaways: 0:00 Introduction 3:15 Cancer in 90% of bones and hospice care 8:30 Choosing to fight: orchiectomy and chemotherapy 12:00 Faith encounter and sudden disappearance of pain 15:30 Three-month scan: no detectable cancer 18:00 Integrative healing: juicing, soursop, frankincense, movement 22:00 Psycho-neuro-immunology and the power of mindset 27:00 The hidden risks of radiation and long-term side effects 32:00 Why nutrition and immune support matter during treatment 35:00 Living Hope Cancer Foundation and “Get Up And Live” 38:00 Prayer, hope, and healing for listeners Resources Mentioned: Living Hope Cancer Foundation - http://getupandlive.org “Love Tap” bracelet - https://www.getupandlive.org/store Mayo Clinic (Referenced during treatment) American Cancer Society (Volunteer work mentioned) Medical Disclaimer: This content is for educational purposes only and is not intended to diagnose, treat, cure, or replace professional medical advice. Always consult your physician or qualified healthcare provider regarding any medical condition or treatment decisions. -----------------------------------------------A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health ThreatGrab my book here: https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering CancerGet it here: https://store.thekarlfeldtcenter.com/products/unleashing-10x-powerPrice: $24.99100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of CancerGet it here: https://store.thekarlfeldtcenter.com/products/healing-withinPrice: $24.99100% Off Discount Code: CANCERPODCAST2-----------------------------------------------Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-473 Overview: Join us as we review long-term outcomes from a recently published trial on prostate-specific antigen (PSA) testing and prostate cancer mortality. Learn how updated evidence informs shared decision-making and balances early detection with potential harms. Equip yourself to guide patients through nuanced discussions on PSA testing's limitations, mortality data, and meaningful clinical impact. Episode resource links: N Engl J Med 2025;393:1669-80. DOI: 10.1056/NEJMoa2503223 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-473 Overview: Join us as we review long-term outcomes from a recently published trial on prostate-specific antigen (PSA) testing and prostate cancer mortality. Learn how updated evidence informs shared decision-making and balances early detection with potential harms. Equip yourself to guide patients through nuanced discussions on PSA testing's limitations, mortality data, and meaningful clinical impact. Episode resource links: N Engl J Med 2025;393:1669-80. DOI: 10.1056/NEJMoa2503223 Recommendation: Prostate Cancer: Screening | United States Preventive Services Taskforce Guest: Robert A. Baldor MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Does nutrition matter when you are facing prostate cancer? In this episode, Dr. Stephen Petteruti lays out a practical, data-driven framework for prostate cancer nutrition, cancer progression, metabolic health, PSA management, and longevity medicine. Portion control, feeding timing, insulin sensitivity, hemoglobin A1C, triglycerides, and visceral fat all matter. He explains why structured eating patterns, net carbohydrate awareness, and metabolic control often outweigh trendy diet labels.Dr. Stephen also addresses high-risk dietary exposures that many overlook: processed meats and nitrites, sodium benzoate, artificial sweeteners and weight gain signals, petroleum-based food dyes, and chronic high-sugar intake in insulin-resistant individuals.Instead of extreme restriction, he advocates strategic elimination of the biggest carcinogenic inputs while preserving quality of life.If you care about longevity, cancer prevention, and metabolic optimization, spend time with this episode of Best Diet for Prostate Cancer | What Actually Matters for Cancer Progression.Enjoy the podcast? Subscribe and leave a 5-star review.Dr. Stephen Petteruti is a board-certified physician specializing in longevity-focused, integrative medicine. He works with men navigating prostate cancer, testosterone and hormone health, aging, and performance using proactive, evidence-informed strategies grounded in real clinical practice. His approach prioritizes preserving function, strength, and quality of life while helping patients make clear, informed decisions beyond reactive, fear-driven care.Learn more: https://www.drstephenpetteruti.com/Learn more: https://www.intellectualmedicine.com/Connect with Dr. Petteruti on:⁠Instagram: ⁠https://www.instagram.com/dr.stephenpetteruti/⁠Facebook: ⁠https://www.facebook.com/dr.stephenpetteruti⁠Subscribe to Intellectual Medicine on:Apple Podcast: https://tinyurl.com/DrPetterutiApplePodcastSpotify: https://tinyurl.com/DrPetterutiSpotifyPodcastDisclaimer:The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

MEDICARE ADVANTAGE MINUTE:                                                                     CMS (THE GOVERNMENT) TAKES AIM AT MEDICARE ADVANTAGE FRAUD Correspondence: Client Mike writes to ask me to find his wife a Plan G Medicare supplement with a better price. Her current Aetna plan has scheduled a $60+ monthly rate increase so Mike asked me to look for a better deal.  Once again I explained the advantages of High Deductible Plan G (HDG) but Mrs. Mike is very risk averse and wants to stay with regular (expensive) Plan G. A few weeks after, Mike contacted me again to announce that he plans to switch to HDG when his state mandated Birthday Rule period came around. Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+)                   Visit us on: BabyBoomer.ORG Inspired by: "MEDICARE FOR THE LAZY MAN 2026; SIMPLEST & EASIEST GUIDE EVER!" "MEDICARE ENROLLMENT GUIDE!" (Free download from site below) "MEDICARE DRUG PLANS: A SIMPLE D-I-Y GUIDE" For sale on Amazon.com. After enjoying the books, please consider returning to leave a short customer review to  help future readers. Official website: https://www.MedicareForTheLazyMan.com.

(00:00:00) The Pennsylvania Human Relations Commission (PHRC) formally released its State of Fair Housing in the Commonwealth of Pennsylvania. The report examines current housing conditions, patterns of discrimination, and structural challenges impacting access and affordability. It also advances key policy and enforcement recommendations, including strengthening protections against source-of-income discrimination, addressing disparate impact and segregation, improving code enforcement and habitability standards, and increasing accountability for affirmatively furthering fair housing. The report brought together state leaders, civil rights advocates, and housing experts to address ongoing disparities and outline a path forward to ensure equal housing opportunity for all Pennsylvanians. (00:22:22)Prostate cancer is a malignant tumor of the prostate gland. The prostate is a walnut-sized organ located in front of a man's rectum and below the bladder. Prostate cancer usually grows slowly, so chances for successful treatment increase if doctors catch the disease early. Your age and the stage of the cancer will help determine your treatment. For some men, doctors recommend active surveillance — closely monitoring the tumor — instead of treatment.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Pippa Hudson speaks to Dr Cleve Oppel, a consultant in the Urology Department at Groote Schuur Hospital, about the risk factors and warning signs of prostate cancer, and also an inspiring initiative which is helping fund additional surgeries to treat prostate cancer and kidney stones in the public sector. Lunch with Pippa Hudson is CapeTalk’s mid-afternoon show. This 2-hour respite from hard news encourages the audience to take the time to explore, taste, read, and reflect. The show - presented by former journalist, baker and water sports enthusiast Pippa Hudson - is unashamedly lifestyle driven. Popular features include a daily profile interview #OnTheCouch at 1:10 pm. Consumer issues are in the spotlight every Wednesday while the team also unpacks all things related to health, wealth & the environment. Thank you for listening to a podcast from Lunch with Pippa Hudson Listen live on Primedia+ weekdays between 13:00 and 15:00 (SA Time) to Lunch with Pippa Hudson broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show, go to https://buff.ly/MdSlWEs or find all the catch-up podcasts here https://buff.ly/fDJWe69 Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Interview with Gennady Bratslavsky, MD, and Hanan Goldberg, MD,

PJ catches up with Cllr Michael Looney who recently told the story of how a lucky catch saved his life so others can be more aware Hosted on Acast. See acast.com/privacy for more information.

PSA spikes, abnormal MRI results, and high PI-RADS scores often trigger immediate fear and for many men, that fear leads straight to biopsy. In this episode, Dr. Stephen Petteruti breaks down what PSA actually measures, how MRI technology fits into modern prostate cancer management, and why a high PI-RADS score does not automatically equal aggressive disease. Dr. Stephen discusses active surveillance, non-biopsy monitoring strategies, cardiovascular risk, hormone balance, and why overtreatment may compromise quality of life more than the cancer itself.  For men who value proactive healthcare, evidence-based medicine, testosterone preservation, and long-term vitality, this conversation offers clarity in a space dominated by urgency and assumption. It reframes prostate cancer care around informed consent, individualized risk assessment, and protecting both lifespan and healthspan.Before agreeing to your next scan or biopsy, press pause. Listen carefully. Ask better questions. Watch the episode of Stop the Prostate Biopsy Frenzy: The Truth About MRI, PI-RADS, and PSA.Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: https://www.drstephenpetteruti.com/ Practice: www.intellectualmedicine.com YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: https://www.instagram.com/dr.stephenpetteruti/ Facebook: https://www.facebook.com/dr.stephenpetteruti    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

SummaryThis Uromigos podcast delves into the evolution and significance of the Prostate Cancer Working Group criteria, highlighting the iterative process of developing guidelines that reflect the latest scientific evidence and clinical practices. The speakers discuss the new PCWG4 including new nomenclature, the role of imaging technologies like PSMA PET, and the importance of biomarkers and patient-reported outcomes in enhancing patient care and treatment efficacy. They emphasize the collaborative nature of the working groups and the ongoing need for adaptation in response to emerging data and technologies.

Tell us about your Adventure!Prostate cancer can be a life-altering diagnosis. For Chris Pedlar from England, it sparked a transformative journey. Chris turned his battle with cancer into a passion for raising awareness about this disease. He actively promotes the importance of early detection through PSA tests and routine examinations. Chris's journey is not merely about surviving; it is a compelling story of resilience, hope, and the critical nature of proactive health measures.

2 mates, Niall & Miki, discussing the day to day struggles in life, from a Man's point of view. This week the boys discuss prostate cancer, a Live power cut while recording and Miki crashed his drone and the fallout. Hope you enjoy...Support the show

On this episode host Jonathan Chance talks with Michael Krachon of Theragenics about the future of prostate cancer treatment. Jonathan and Michael talk about.·       Researching prostate cancer treatment options before meeting with your doctor.·       What is LDR brachytherapy for treating prostate cancer.·       The current need to increase awareness about LDR brachytherapy.·       How Theragenics is helping drive the future of isotope-based cancer treatments?·       What newly diagnosed prostate cancer patient should know about treatment options.For more information about brachytherapy and prostate cancer, visit Theragenics website at: LifeAfterSeeds.com  Prostate Cancer Aware is grateful to the Jevan and Ruzanna Chimayan Foundation for their generous donation, which will help fuel our podcast and website to raise critical awareness about prostate cancer and the PSA test around the world.Prostate Cancer Aware is a copyrighted production. No content maybe rebroadcast or reproduced without the expressed written consent of the Friedman Sidrow Foundation. For more information about prostate cancer, the PSA test, men's health and Jonathan's inspiring new book Unaware, which is about his battle with prostate cancer. Visit our website at: https://www.iknowmypsa.org Email us at: https://www.iknowmypsa.org/contactus/ Follow Prostate Cancer Aware on social media at: Facebook - https://www.facebook.com/iknowmypsa Twitter - https://twitter.com/iknowmypsa or @iknowmypsa Thank you for listening! Remember, Stay Aware and Stay Healthy.™

Most men believe their sex life is a mechanical issue—a matter of "equipment" and blood flow. But what if the greatest barrier to your sexual recovery isn't your prostate surgery, but an invisible biological "imprint" created by your smartphone? We are currently living through a global "sex recession" where AI and digital technology are fundamentally reprogramming the human arousal template before we even touch another person. For the man facing prostate cancer, this digital shift, combined with the "Masculinity Paradox," creates a perfect storm of sexual isolation.Joining us to navigate this landscape is Dr. Marianne Brandon, a world-renowned licensed clinical psychologist, diplomate in sex therapy, and co-host of The Sex Doctors. With nearly thirty years of clinical experience and a deep focus on the intersection of evolutionary biology and sex tech, Dr. Brandon offers a radical roadmap for reclaiming your power in the bedroom.In this episode, you'll learn:Why your "Arousal Template" might be working against your recovery and how to reset it.The "Lingerie & Music" strategy for bypassing the anxiety that shuts down your nervous system.Why post-prostatectomy orgasms can actually be more intense than before surgery.Practical clinical hacks for managing "Climacturia" (leaking during climax) without killing the mood.Podcast “The Sex Doctors” https://www.youtube.com/@thesexdoctorspod/videosWebsite: www.drbrandon.net (http://www.drbrandon.net)Seminars:https://www.tzkseminars.com/marianne-brandon-phd/___________________________________

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in this population, the importance of PSA doubling time as a prognostic factor and with an emphasis on treatment de-escalation to limit toxicity and improve patient outcomes. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO authors Dr. David Einstein and Dr. Ravi Madan. Dr. Einstein is a medical oncologist specializing in genitourinary malignancy working at Beth Israel Deaconess Medical Center, part of the DFCI Cancer Center, and an assistant professor at Harvard Medical School. Dr. Madan is a senior clinician at the National Cancer Institute (NCI), where he focuses on conducting clinical research in prostate cancer, particularly in the field of immunotherapy. Today, we will be discussing the article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." So, thank you for speaking with us, Dr. Einstein and Dr. Madan. David Einstein: Thanks for having us. This is a great pleasure. Ravi Madan: Appreciate being here. Davide Soldato: So, I just want to start from a very wide angle. And the main question is why did you feel that there was the need to convey a consensus and a working group to talk about this specific topic: biochemically recurrent prostate cancer? What has been the change in current clinical practice and in the trial design that we are seeing nowadays? And so, why was it necessary to convey such a consensus and provide considerations on novel clinical trials? David Einstein: Yeah, so I think it's very interesting, this disease state of biochemically recurrent prostate cancer. It's very different from other disease states in prostate cancer, and we felt that there was a real need to define those differences in clinical trials. Years ago, metastatic castration-resistant prostate cancer was the primary disease state that was explored, and over time, a lot of things shifted earlier to metastatic disease defined on a CAT scan and bone scan to an earlier disease state of metastatic castration-sensitive prostate cancer. And the clinical trial principles from late-stage could be applied to MCSPC as well. However, BCR is very different because the patients are very different. And for those reasons, there are unique considerations, especially in terms of toxicity and treatment intensity, that should be applied to biochemically recurrent prostate cancer as opposed to just using the principles that are used in other disease states. And for that reason, we thought it was very important to delineate some of these considerations in this paper with a group of experts. Davide Soldato: Thanks so much. So, one of the main changes that have been applied in recent years in clinical practice when looking at biochemically recurrent prostate cancer is the use of molecular imaging and particularly of PSMA PET. So, first of all, just a quick question: was the topic of the consensus related on which threshold of PSA to use to order a PET scan to evaluate this kind of patient? David Einstein: Yeah, thanks for that question. It's a super important one. The brief answer is that no, we did not address questions about exactly when clinicians would decide to order scans. We were more concerned with the results of those scans in how you define different disease states. But I think as a broader question, I think a lot of folks feel that finding things on a scan equates that with what we used to find on conventional scans. And fundamentally, we actually sought to redefine that disease space as something that's not equivalent to metastatic disease, and rather coined the term "PSMA-positive BCR" to indicate that traditional BCR prognostic criteria and factors still apply, and that these patients have a distinct natural history from those with more advanced metastatic disease. Ravi Madan: And if I may just add that the National Cancer Institute is running a trial where we're prospectively monitoring PSMA-positive BCR patients. And that data is clearly showing that, much like what we knew about BCR a decade ago, PSMA findings in BCR patients do not change the fact that overall, BCR is an indolent disease state. And the findings, which are usually comprised of five- to seven-millimeter lymph nodes, do not endanger patients or require immediate therapy. And so, while PSMA is a tool that we can be using in this disease state, it doesn't really change the principal approach to how we should manage these patients. And as Dr. Einstein alluded to, there is a drive to create a false equivalency between PSMA-positive BCR and metastatic castration-sensitive prostate cancer, but that is not supported by the data we're accumulating or any of the clinical data as it exists. Davide Soldato: One thing that it's very important and you mentioned in your answer to my question was actually the role of PET scan and conventional imaging, so CAT scan and bone scan that we have used for years to stage patients with metastatic prostate cancer. And you mentioned that there is a distinction among patients who have a positive PET scan and a BCR, and patients who have a positive conventional imaging. And yet, we know that sometimes the findings of the PET scan are not always so clear to interpret. So, I just wanted to understand if the consensus reached an agreement as to when to use conventional imaging to potentially resolve some findings that we have on PET scan among thess patients with BCR? David Einstein: Yeah, I think there's a number of questions actually buried within that question. One of which is: does PSMA PET result in false positives? And the answer has definitely been yes. There's a known issue with false-positive rib lesions. And so, first and foremost, we need to be very careful in calling what truly is suspicious disease and what might actually not be cancer or might be something that is totally separate. So I think that's the first part of the answer to that question. The second is to what extent do we need to use paired PET and conventional imaging to define this disease state? In other words, do you have to have positive findings on one and negative findings on the other in order to enter this definition? The challenge there, as we discussed, is that logistically, oftentimes it's hard to get patients to do multiple sets of scans to actually create that definition. Sometimes it's difficult to get insurers to pay for such scans. And finally, it's hard to sometimes blind radiologists to the results of one scan in reading the other. So, we did have some deliberations about to what extent you could use some of the CAT scan portion of a PSMA PET in order to at least partially define that. We also talked about using bone scans to confirm any bone findings seen on PET. But I think another important part of this is not just the baseline imaging, but also what's going to be done serially on a study in order to define responses and progression. And that's sort of a whole separate conversation about to what extent you can interpret changes in serial PET. Ravi Madan: And just to pick up on the key factor here, I think that the PSMA PET in BCR is pretty good at defining lymph node disease, and that's actually predominantly 80 to 90 percent of the disease seen on these findings. It might be pretty good at also defining other soft tissue findings. The real issues come to bone findings. And one thing the group did not feel was appropriate was to just define only PSMA-positive bone findings confirmed on a CT bone window. There's not really great data on that, but the working group felt that, when in the rare situation, because it is relatively rare, a PSMA-positive finding is in a bone, a bone scan should be done. And it's worth noting that Phu Tran, who is a co-author and a co-leader of this working group, his group has already defined that underlying genomics of conventionally based lesions, such as bone scan, are more aggressive than findings on next-gen imaging, such as PSMA. So, there is also a genomic underlying rationale for defining the difference between what is seen on a PET scan in a bone and what is seen on a bone scan. Davide Soldato: Coming back to this issue of PET PSMA sometimes identifying very small lesions where we don't see any kind of correlates on conventional imaging or where we see only very little alteration on the bone scan or in the CT scan, was there any role that was imagined, for example, for MRI to distinguish this type of findings on the PET scan? Ravi Madan: So, I think that, again, what can be identified on a PSMA frequently cannot be seen on conventional imaging. We didn't feel that it was a requirement to get an MRI or a CT to necessarily confirm the PSMA findings. I think that generally, we have to realize that in this disease state, that questionable lesions are going to be seen on any imaging, including PSMA. We've actually probably put way too much faith in PSMA findings thus far, as Dr. Einstein alluded to with some of the false positives we're seeing. So, I think that these false positives are going to have to be baked into trials. And in terms of clinical practice, it highlights the need to again, not overreact to everything we see and not necessarily need to biopsy everything and put patients' health in jeopardy to delineate a disease that's indolent anyway. Davide Soldato: Thanks so much. That was very clear. So, basically, the main driver was really also the data showing that if we have a BCR, so a patient with a biochemically recurrent disease that is positive on the conventional imaging, this is usually associated with a different aggressiveness of the disease. But coming back to a comment that you made before, Dr. Madan, you said that even if we talk about PSMA-positive BCR, we are still talking about BCR and the same criteria should apply. So, what we have used for years in this space to actually try to stratify the prognosis of patients is the PSA doubling time, so how quickly the PSA rises over time. So, coming back to that comment, was the consensus on the PSA doubling time basically retained as what we were using before, so defining patients with a doubling time less than 12 months, 10 months, 9 months, as patients with a higher risk of progressing in terms of developing metastatic disease? Ravi Madan: Yes, so that's a very important point. And the working group defined high-risk BCR as a PSA doubling time less than six months. And this really comes from Johns Hopkins historical data, which shows that if your doubling time is three months or less, there's about a 67 percent chance of metastasis at five years. If it's between three and six months, it's 50 percent. And if it's over six months, if it's between six and nine months, it's roughly only 27 percent. There are trials that are accruing with eligibility criteria that they may describe as high-risk that are beyond six months, but the data as really it's been defined in the literature highlights that truly high-risk BCR is less than six months. And the working group had a consensus on that opinion, and that was our recommendation. David Einstein: And I think an important follow-on to that is that's regardless of PET findings, right? And so, we present a couple of case studies of patients with positive PET findings who have a long doubling time, in whom the disease is in fact indolent, as you would have expected from a traditional BCR prognostic standpoint. Obviously, there are patients in whom they have fast doubling times, and even if they do not have PET findings, that doesn't make them not high-risk. Ravi Madan: And just to follow up that point, I will let you know a little bit of a free preview that my colleague Melissa Abel from the NCI will be presenting PSMA findings in the context of PSA doubling time at ASCO GU if that data is accepted. Davide Soldato: Looking forward for those data because I think that they're going to clarify a lot of the findings that we have in this specific population. And coming back to one of the points that we made before, so PET PSMA has a very high ability to discriminate also a very low burden of disease, which we currently refer to as oligometastatic biochemically recurrent prostate cancer, which is not entirely defined as an entity. But what we are seeing both in some clinical trials, which use mainly conventional imaging, but also what we're starting to see in clinical practice, is that frequently we use the metastasis-directed therapy to treat these patients. So, just a little bit of a comment on the use of this type of strategy in clinical practice and if the panel thought of including this as, for example, a stratification criteria or mandated in the design of novel clinical trials in the field of BCR? David Einstein: Yeah, I think that's an incredibly important point. You know, fundamentally, there's a lot of heterogeneity in practice where some folks are using local salvage approaches, some are using systemic therapies, in some cases surveillance may be reasonable, or some combination of these different strategies. We certainly have phase two data from multiple trials suggesting that met-directed therapy may help buy patients time off of treatment until subsequent treatments are started. And that in and of itself may be an important goal that we can come back to in discussing novel endpoints. I think what our panel acknowledged was that, in some sense, the clinical practice has gotten even farther ahead than where the data are, and this is being offered pretty routinely to patients in practice. And so, what became clear was that we, in developing clinical trials, cannot forbid investigators from doing something that would be within their usual standard of care, even if it might not be supported by the most robust data. But at minimum, it definitely should be used as a stratification factor, or in some trial designs, you can do met-directed therapy after a primary endpoint is assessed. And that offers a compromise between testing, say, the effect of a systemic therapy but also not excluding patients and investigators from doing what they would have done had they not been on a study. Ravi Madan: And I would just like to follow up your phrasing in the question of "oligometastatic prostate cancer." We have a figure in the paper and it highlights the fact that, unfortunately, that term in prostate cancer is imaging agnostic. And we've already discussed in this podcast, as well as in the paper, that imaging used to define a metastatic lesion, whether it's PSMA or conventional imaging, carries with it a different clinical weight and a different prognosis. So, we feel in the working group, that the correct term for this disease state of PSMA-positive BCR is just that: PSMA-positive BCR. We also have to realize that when we talk about oligometastatic disease, while it's imaging agnostic, it seems to be numerically based, whether it's five or three or 10 depending on the trial. But PSMA-positive BCR does not have a limit in terms of the number of lesions. And so again, we just feel that there is an important need to delineate what we're seeing in this disease state, which again is PSMA-positive BCR, and that should be differentiated frankly from oligometastatic disease defined on other imaging platforms. David Einstein: Right, and that also makes clear that patients can have polyfocal disease on PET that still is not what we would consider metastatic, but goes beyond the traditional definition of oligometastatic. So, in other words, just because someone has PET-detected disease only, that does not automatically equate with oligometastatic. Davide Soldato: Thanks so much. So, you were speaking a little bit, Dr. Einstein, about the different types of treatment that we can propose or not propose to this patient because you mentioned, for example, that in clinical practice MDT, so metastasis-directed therapy, is becoming more and more used. For these patients, we can potentially use systemic treatments, which include androgen deprivation therapy, which can be given continuously or in an intermittent fashion. And recently, we can also use novel systemic therapies, for example, enzalutamide, to treat this type of patient. So, given that the point of the consensus was really to provide consideration for novel clinical trials in this space, what was the opinion on the panel regarding the control arm? So, if we're looking at a novel therapy in the BCR space, does the control arm need to include a therapy or not? And if so, which therapy? David Einstein: Yeah, this is a super important question and one that's subject to a lot of discussion, especially in light of recent data from EMBARK. What we came to a consensus around was the fact that neither MDT nor systemic therapy should be required as a control arm on BCR trials. And we can talk about a number of reasons for that. There's also the pragmatics of what investigators might actually accrue patients to and what they would consider their standard of care, and that's important to factor in, too. I think that one of the major goals of our working group was outlining what kinds of trials we would like to see in the future and where the limitations of the current data stand. For example, EMBARK proposes a strategy of a single treatment discontinuation and resumption at a predefined threshold indefinitely. That's probably not how most people are practicing. Most folks are probably using some version of intermittent therapy as they would have before this trial, but we actually don't have any data supporting that. Moreover, we don't have data comparing different intermittent strategies to one another. We don't know what the right thresholds are, we don't know how much time we buy patients off treatment, and we don't know to what extent MDT modifies that. And so, those are all really important questions to be asking in future versions of these trials. I'd say my second point would be that a lot of drug development is happening with novel therapies that are not hormonal, trying to bring them into this space. And when you think about trying to compare one of those types of therapies to a hormonal therapy on short-term endpoints, the hormonal therapy is always going to win. Hormonal therapy is almost universally effective, it will bring down PSAs, and it will prolong, quote-unquote, "progression." The downside of that is that hormonal therapy doesn't actually modify the disease, it suppresses it, and it tends to have fairly transient effects once you remove it. And so, part of our goal was in trying to figure out some novel endpoints that would allow these novel types of therapies to be examined head-to-head against a more traditional type of hormonal therapy and have some measurement of some of the more long-term impacts. Davide Soldato: So, jumping right into the endpoints, because this is a very relevant and I think very well-constructed part of the paper that you published. Because in the past we have used some of these endpoints, for example, metastasis-free survival, as potentially a proxy for long-term outcomes. But is this the right endpoint to be using right now, especially considering that frequently this outcome is measured using conventional imaging, but we are including in these trials patients who are actually negative on conventional imaging but have a positive PSMA when they enter this type of trial? David Einstein: Yeah, there's a number of challenges with those types of endpoints. One of which is, as you say, we're changing the goalposts a little bit on how we're calling progression. We still don't exactly understand what progression on PET means, and so that's something that is challenging. That said, we're also cognizant of the fact that many times investigators are likely to get PET scans in the setting of rising PSA, and that's going to affect any endpoint that relies purely on conventional imaging. So, there's some tension there between these two different sets of goalposts. One thing that we emphasize is that not only are there some challenges in defining those, but also there're challenges in what matters to a patient. So, if a progression event occurs in the form of a single lesion on a PET scan or even a conventional image, that might be relevant for a clinical trial but might be less relevant for a patient. In other words, that's something that, in the real world, an investigator might use serial rounds of metastasis-directed therapy or intermittent therapy to treat in a way that doesn't have any clinical consequences for the patient necessarily. In other words, they're asymptomatic, it's not the equivalent of a metastatic castration-resistant disease progressing. And so, we also need to be cognizant of the fact that if we choose a single endpoint like PFS, that there's going to be many different versions of progression, some of which probably matter clinically more than others, and some of which are more salvageable by local therapies than others. Ravi Madan: So I think the working group really thoughtfully looked at the different options and underscored perhaps strengths and weaknesses, and I think that's presented as you mentioned in the paper. But I think it's also going to depend on the modality, the approach of the therapeutic intervention. In some cases if it's hormone-based, then maybe PSA is providing some early metrics, maybe metastasis-free survival is more relevant in a continuous therapy, but intermittent therapies might have a different approach. There's emerging immunotherapy strategies, radiopharmaceutical strategies, they might have some more novel strategies as well. I think we have to be open-minded here, but we also have to be very clear: we do not know what progression is on a PSMA scan. Just new lesions may not carry the clinical significance that we think, and we may not know what threshold that ultimately becomes clinically relevant is. So, I do think that there was some caution issued by the working group about using PSMA as an endpoint because we still do not have the data to understand what that modality is telling us. Again, I'm optimistic that the National Cancer Institute's prospective data set that we've been collecting, which has over 130 patients now, will provide some insights in the months and years ahead. Davide Soldato: So, just to ask the question very abruptly, what would you feel like the best endpoint for this type of trials is? I understand that is a little bit related to the type of treatments that we're going to use, whether it's intermittent, whether it's continuous, but do we have something that can encapsulate all of the discussion that we have up until this point? David Einstein: Yeah, so that's a perfect segue to the idea of novel endpoints, which we feel are very important to develop in these novel disease spaces. So, one thing that we discussed was an endpoint called treatment-free survival, which conceptually you can think of as exactly what it sounds like, but statistically you actually have to do some work to get there. And so essentially, you imagine a series of Kaplan-Meier curves overlaid: one about overall survival, one time to next therapy, one time on initial therapy. You can actually then take the area under those curves or between those curves and essentially sum it up using restricted mean survival time analysis. And that can give you a guide about the longitudinal experience of a patient: time spent on treatment versus off treatment; time spent with toxicity versus without toxicity. And importantly, each one of those time-to-event metrics can be adjusted depending on exactly what the protocol is and what is allowed or not allowed and what's prespecified as far as initiation of subsequent therapies. So, we felt that this was a really important endpoint to develop in this disease space because it can really capture that longitudinal aspect. It can really reward treatments that are effective in getting durable responses and getting patients off of therapy, because unfortunately, PFS-based endpoints generally reward more or longer systemic therapy versus shorter or no systemic therapy, and that's sort of an artificial bias in the way those endpoints are constructed. So, I think that there are challenges of course in implementing any new endpoint, and some of the things that are really critical are collecting data about toxicity and about subsequent therapies beyond what a typical trial might collect. But I think in this kind of disease space, that longitudinal aspect is critical because these are really patients who are going to be going through multiple rounds of therapy, going to be going on and off treatments, they're going to be using combinations of local and systemic therapies. And so, any one single endpoint is going to be limited, but I think that really highlights the limitations of using PFS-based endpoints in this space. Ravi Madan: I also think that in the concept of treatment-free survival lies one of the more powerful and, honestly, I was surprised by this, that it was so universally accepted, recommendations from the committee. And that was that the general approach to trials in this space should be a de-escalation of the EMBARK strategy as it's laid out with relatively continuous therapy with one pause. And so, I think again, buried in all of this highlights the need for novel endpoints like treatment-free survival. We get to the fact that these are patients who are not at near-term clinical risk from symptoms of their disease, so de-escalating therapies does not put them at risk. And if you look at, for example, lower-volume metastatic castration-sensitive prostate cancer, it's become realized that we need to de-escalate, and there are now trials being done to look at that. Historically, we know that BCR is an indolent disease process for the vast majority of patients who are not at near-term risk from clinical deterioration. So, therefore, we shouldn't wait a decade into abundant BCR trials to de-escalate. The de-escalation strategy should be from the outset. And that was something the committee really actually universally agreed on. David Einstein: And that de-escalation can really take multiple forms. That could be different strategies for intermittent therapy, different start-stop strategies. It could also mean actually intensifying in the short-term with the goal long-term de-intensification, kind of analogous to kidney cancer where we might use dual checkpoint inhibitors up front with some higher upfront toxicity but with the hope of actually long-term benefit and actually being able to come off treatment and stay in remission. Those kinds of trade-offs are the types of things that are challenging to talk about. There's not a one-size-fits-all answer for every patient. And so, that's why some of these endpoints like treatment-free survival would be really helpful in actually quantifying those trade-offs and allowing each patient to make decisions that are concordant with their own wishes. Davide Soldato: Thanks so much. That was very clear, especially on the part of de-escalation, because, as you were mentioning, I think that we are globally talking about a situation, a clinical situation, where the prognosis can be very good and patients can stay off treatment for a very long period of time without compromising long-term outcomes. And I think that well-constructed de-escalation trials, as you were mentioning and as the consensus endorsed, are really needed in this space also to limit toxicity. This brings us to the end of this episode. So, I would like to thank again Dr. Einstein and Dr. Madan for joining us today. David Einstein: We really appreciate the time and the thought, and I think that even starting these types of discussions is critical. Even just recognizing that this is a unique space is the beginning of the conversation. Ravi Madan: Yeah, and I want to thank JCO for giving us this forum and the opportunity to publish these results and all the expert prostate cancer investigators who were part of this committee. We produced some good thoughts for the future. Davide Soldato: We appreciate you sharing more on your JCO article titled, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DBK865. CME/NCPD/CPE/AAPA/IPCE credit will be available until February 8, 2027.Paving the Path for Optimal Prostate Cancer Care: Preparing Advanced Practice Providers to Integrate Modern Therapies Into Tailored Treatment Plans In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc.Disclosure information is available at the beginning of the video presentation.

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: EMBARK trial: Enzalutamide for biochemically recurrent prostate cancer (0:00) Final results from the Phase III PRESTO study: Combined androgen blockade for high-risk biochemically relapsed prostate cancer (4:05) Other novel treatment strategies for patients with metastatic prostate cancer (10:31) CME information and select publications

A diagnosis and even aggressive treatment does not have to mark the end of strength, intimacy, or confidence. In this episode, Dr. Stephen Petteruti speaks directly to men navigating erectile dysfunction, low testosterone, and Peyronie's disease after prostate cancer treatment, reframing recovery around vitality rather than fear. He challenges the idea that sacrificing sexual health is the price of survival and explains why health span and sex span matter as much as lifespan. With a focus on regeneration and informed decision-making, Dr. Stephen outlines how carefully managed testosterone support, vascular health strategies, and tissue-preserving approaches can help men restore energy and sexual function. The discussion emphasizes critical thinking, patient autonomy, and the importance of treating men, not just lab numbers.Question the assumptions you've been given and decide how fully you want to live moving forward. Watch the episode of ED, Low Testosterone and Peyronie's After Prostate Cancer Treatment.Enjoy the podcast? Subscribe and leave a 5-star review.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: https://www.drstephenpetteruti.com/ Practice: www.intellectualmedicine.com YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: https://www.instagram.com/dr.stephenpetteruti/ Facebook: https://www.facebook.com/dr.stephenpetteruti    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

Dr McKay discusses the selection of and efficacy data with androgen pathway-targeting agents for patients with prostate cancer and reviews recently presented clinical findings from the ESMO Congress 2025.CME information and select publications here.

In this an honest and emotional episode of The Penis Project Podcast, Melissa and Kate shift the spotlight to a voice that is far too often missing in prostate cancer conversations — the partner.  Rachel bravely shares her lived experience of navigating intimacy, grief, love, patience, and reconnection after her partner underwent prostate cancer surgery. What unfolds is not a clinical education session, but a raw, validating conversation about what happens to relationships when erections, continence, desire, and confidence change overnight.  Together, they explore how prostate cancer is not just a medical diagnosis, it is a life changing event. One that impacts communication, identity, sexuality, and emotional safety on both sides.  This episode is essential listening for partners, couples, and clinicians who want to better understand the unseen emotional labour carried by those standing beside the man with the diagnosis.  In This Episode, We Discuss:  Why prostate cancer is a couple's condition, not just a men's health issue  The silent grief partners experience   Why erectile dysfunction, incontinence, and medicalised sex can affect intimacy  Feeling out of sync: when one partner is focused on survival and the other on connection  The loss of spontaneity, desire signals, and sexual confidence  The emotional complexity of “being supportive”  Why saying “I don't mind if we never have sex again” can feel like rejection  The impact of ED on a partner's sense of desirability and femininity  Navigating injections, pumps, implants   Shifting from performance and penetration to connection and shared pleasure  Practical strategies that may help   Key Takeaways  Desire doesn't disappear after prostate cancer — it changes shape.  Partners grieve too, and their pain deserves space and validation.  Intimacy is about connection, not outcomes.  Support for partners is a glaring gap — and one that must be addressed.  Support for Partners  If you are a partner navigating life after prostate cancer and would like to connect with others in a similar situation, you can email: admin@rshealth.com.au  (Your details can be passed on confidentially — partner anonymity respected.)    Resources & Links:  Book an in clinic or telehealth consult with our sexual health practitioners at Restorative Health Clinic  For more information check out our websites www.rshealth.com.au , www.makehardeasy.com.au and www.melissahadleybarrett.com  Book: Come Together – Emily Nagoski  Listen & Subscribe  If you found this episode helpful, don't forget to subscribe, rate, and review the podcast! Your feedback helps us continue bringing important conversations to light. Search for The Penis Project Podcast on Spotify, Apple Podcasts, or your favourite podcast app.  Connect With Us   We love hearing from real people, navigating penile health. If you'd like to share your journey or ask a question, get in touch. Email: admin@rshealth.com.au    Websites:  https://rshealth.com.au/  All genders  https://makehardeasy.com.au   https://melissahadleybarrett.com   Instagram:  https://www.instagram.com/melissahadleybarrett/  https://www.instagram.com/restorativehealth.clinic/  YouTube: https://www.youtube.com/@melissahadleybarrett   TikTok: @melissahadleybarrett  Facebook:  https://m.facebook.com/p/Melissa-Hadley-Barrett-100085237672685/  https://www.facebook.com/profile.php?id=100085146627814  Linkedin:  https://www.linkedin.com/in/melissa-hadley-barrett/   TEDX:  https://www.youtube.com/watch?v=IjHj1YTmLoA   

In this episode of Med School Minutes, we sit down with Dr. Arthur Burnett, a Johns Hopkins urologist, researcher, and professor whose work helped unlock the science behind Viagra and reshape how medicine understands male sexual health.In recognition of Black History Month, we reflect on Dr. Burnett's groundbreaking career, his impact on men's health research, and the importance of representation and mentorship in medicine.From nitric oxide and vascular health to aging, prostate cancer, and longevity, this conversation explores how scientific discovery shapes both medicine and culture, and what future physicians should know.

In this episode, UROONCO PCa associate editor Prof. Claudia Kesch (DE) interviews Dr. Jochen Walz (FR) about the key highlights of 2025 in low- to intermediate-risk prostate cancer.They discuss advances in imaging diagnostics, artificial intelligence and biomarkers, active surveillance, surgical techniques and radiotherapy, as well as what is anticipated in 2026. Here are the links to the articles and interviews on the trials which were mentioned in this podcast: OPTIMUM TrialPRIME TrialBARCODE1 studyNeuroSAFE PROOF trial resultsENZARAD trial  For more updates on prostate cancer, please visit our educational platform UROONCO PCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Prostate MRI is changing how clinicians decide when a biopsy is needed and how sampling is targeted to better detect clinically significant prostate cancer. In this episode of Better Edge, Hiten Patel, MD, discusses MRI‑informed risk stratification, including the use of an MRI‑based risk calculator, and how MRI‑targeted biopsy can reduce missed high‑grade disease. The episode also highlights how PSA density informs decision‑making after a negative MRI and how to manage discordant targeted and systematic biopsy results. Dr. Patel reviews lesion characteristics, like size and suspicion score, in the context of follow‑up and treatment intensity, along with emerging tools like PSMA PET and AI that may further refine detection and biopsy targeting.

The Clare based chair of HSE MidWest's Patient and Service User Council is imploring people not to take good health for granted and to regularly check themselves for a cancer diagnosis.Today, February 4th is World Cancer Day, and in Ireland over 44,000 new cases are detected each year.In 2017, Quin Native John Wall was diagnosed with stage 4 prostate cancer, having presented to his GP, believing there was an issue with his sciatica. John says the importance of early detection cannot be emphasised enough.

When is active surveillance the right choice for intermediate-risk prostate cancer patients? In this episode of BackTable Urology, Dr. Claire de la Calle, Assistant Professor of Urology at the University of Washington, joins Dr. Ruchika Talwar to unpack how active surveillance has evolved beyond low-risk disease and why select Grade Group 2 patients may be appropriate candidates now with thoughtful patient selection. --- SYNPOSIS The conversation explores emerging tools that can refine surveillance decisions, including PSA density, MRI findings, genomic classifiers, and the growing role of AI-assisted pathology. Dr. de la Calle emphasizes the importance of nuanced patient counseling, acknowledging anxiety and long-term risk while reinforcing that time on active surveillance can be a meaningful win when oncologic outcomes remain comparable to upfront treatment. --- TIMESTAMPS 00:00 - Introduction02:58 - Current Evidence05:03 - Patient Selection Criteria12:11 - Importance of PSA Density and Monitoring Protocols18:12 - Pathology and Genomic Testing32:18 - Future Directions and Research36:33 - Key Takeaways --- RESOURCES ProtecT Trial: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancerhttps://www.nejm.org/doi/full/10.1056/NEJMoa2214122 Canary PASS Studyhttps://canarypass.org/ Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trialhttps://pubmed.ncbi.nlm.nih.gov/37137444

Movement builds strength, resilience, and confidence. Even small, consistent actions can protect your future. In this episode, Dr. Stephen Petteruti walks through how specific types of exercise influence prostate cancer progression, cardiovascular risk, and long-term vitality. He explains why even modest, consistent activity can slow disease progression and reduce the risk of the most common cause of death in men with prostate cancer which is heart disease. Dr. Stephen highlights minimum effective strategies which include brisk walking, interval-style cardio, and compound strength training that fit into real lives.You'll hear common fears around testosterone and exercise, clarifying why strength training and short bursts of cardiovascular activity support hormonal balance, muscle, bone health, and confidence without increasing cancer risk. Practical insights on time efficiency, injury prevention, and sustainable habits make the guidance actionable rather than overwhelming.If longevity, resilience, and quality of life matter as much as lab numbers, this episode offers a smarter framework. Watch now: How Exercise Impacts Prostate Cancer Outcomes.Enjoy the podcast? Subscribe and leave a 5-star review on your favorite platforms.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: https://www.drstephenpetteruti.com/ Practice: www.intellectualmedicine.com YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: https://www.instagram.com/dr.stephenpetteruti/ Facebook: https://www.facebook.com/dr.stephenpetteruti    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

Today's guest is Tony Collier BEM, who has been living with advanced stage prostate cancer since 2017. He is an avid runner, prostate cancer advocate and awareness speaker, and an encourager of those living with and beyond cancer to exercise for continued health. He was also awarded the British Empire Medal in 2019 for his work in the re-generation of his home town and his charity fundraising.We talk about the importance of exercise before, during and after cancer treatment, mental health and psychosexual therapy, better prostate cancer screening and education, peer to peer support, and so much more!!Thriving with cancer isn't just about medical treatments. There is so much more to health and this is the conversation that delves into all of it.Resources:Tackle Prostate Website: https://tackleprostate.org/Tony's Blog: https://runningintocancer.co.uk/Tony's LinkedIn: https://www.linkedin.com/in/tony-collier/Follow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

In this conversation, Vindog, also known as Vincent LeVine, shares his personal journey with prostate cancer, detailing the initial diagnosis, the emotional turmoil that followed, and the various treatment options he considered. He emphasizes the importance of PSA testing and early screening, discusses the biopsy process, and weighs the pros and cons of surgery versus radiation. Throughout the discussion, Vindog highlights the significance of community support and humor in coping with cancer, ultimately recommending radiation treatment based on his positive experience. He also touches on the ongoing need for monitoring and the psychological aspects of living with cancer.#prostatecancer

Is the biopsy needle more dangerous than the cancer itself? In this episode, Dr. Geo sits down with Dr. Mark Emberton, Dean of Medical Sciences at UCL and a global leader in urologic oncology. We dive deep into the "See and Treat" revolution—a massive shift in prostate cancer care that moves away from "blind" invasive biopsies toward precision imaging like MRI and PSMA PET scans.Dr. Emberton explains why many prostate cancers found through traditional methods are "biological non-events" that never needed treatment, and how younger men (ages 40-50) can better navigate their diagnosis. We also discuss the future of focal therapy, the role of AI in radiology, and the groundbreaking "Transform" study that aims to change prostate screening forever.WHAT YOU'LL LEARN IN THIS EPISODE:✅ Why a normal MRI (PI-RADS 1-2) might mean you can skip the biopsy entirely.✅ The difference between "visible" tumors on imaging vs. microscopic disease.✅ How PSA density acts as the crucial "tie-breaker" for indeterminate results.✅ The future of "See and Treat": Targeting lesions while avoiding surgery side effects.✅ Why tumor location (Anterior vs. Posterior) changes your treatment options.✅ How AI and new magnets are making MRI screening cheaper and faster.

In this episode of the ACRO Podcast, ACRO Committee Member Dr. Nevine Hanna is joined by radiation oncologist Dr. Christopher Lee to discuss how genomic testing is refining risk stratification for patients with intermediate risk prostate cancer. He shares insights on integrating genomic data with clinical factors to guide decisions around active surveillance, radiation therapy, and determining which patients may benefit from androgen deprivation therapy (ADT) post-radiation. The conversation highlights practical takeaways for clinicians focused on more personalized, evidence based prostate cancer care.This episode of the ACRO Podcast is sponsored by Myriad Oncology.

Rob Gronkowski and former NFL head coach Bruce Arians stop by to share a sneak peek at their Super Bowl ad aimed at raising awareness and support for prostate cancer screenings. Also, a closer look at a new Common Sense Media report on teenage boys and gambling. Plus, Katherine LaNasa joins to discuss the whirlwind rise in popularity her show ‘The Pitt' has had and what's in store for Season 2. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to this past episode from the Modern Pleasure Podcast where Kim talks to Dr. Jenni and her husband, Daniel Lebowitz on the subject of ED. Daniel explains how ED plagues both the partnership and the man, but how important it is for the penis to be the signal, acting like a lightning rod for your needs, wants, fears and boundaries. Daniel also covers important facts around prostate surgery. See omnystudio.com/listener for privacy information.

Featuring patient case presentations by Dr Fern Anari and Dr Catherine Fahey, with commentary from Dr Matthew D Galsky, including the following topics: AKT inhibitors for PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (0:00) Radioligand-directed therapy for PSMA-positive metastatic hormone-sensitive prostate cancer (8:18) Radiation therapy in combination with enzalutamide for high-risk localized prostate cancer (13:14) CME information and select publications

Dr Rana R McKay discusses the selection and sequencing of therapy for patients with prostate cancer in a review of recently presented clinical findings from ESMO Congress 2025.CME information and select publications here.

Is the biopsy needle more dangerous than the cancer itself? In this episode, Dr. Geo sits down with Dr. Mark Emberton, Dean of Medical Sciences at UCL and a global leader in urologic oncology. We dive deep into the "See and Treat" revolution—a massive shift in prostate cancer care that moves away from "blind" invasive biopsies toward precision imaging like MRI and PSMA PET scans.Dr. Emberton explains why many prostate cancers found through traditional methods are "biological non-events" that never needed treatment, and how younger men (ages 40-50) can better navigate their diagnosis. We also discuss the future of focal therapy, the role of AI in radiology, and the groundbreaking "Transform" study that aims to change prostate screening forever.WHAT YOU'LL LEARN IN THIS EPISODE:✅ Why a normal MRI (PI-RADS 1-2) might mean you can skip the biopsy entirely.✅ The difference between "visible" tumors on imaging vs. microscopic disease.✅ How PSA density acts as the crucial "tie-breaker" for indeterminate results.✅ The future of "See and Treat": Targeting lesions while avoiding surgery side effects.✅ Why tumor location (Anterior vs. Posterior) changes your treatment options.✅ How AI and new magnets are making MRI screening cheaper and faster.

A diagnosis should never strip a man of strength, vitality, or hope but rather push medicine to think deeper, not narrower. In this episode, Dr. Stephen Petteruti challenges one of the most deeply rooted assumptions in prostate cancer care that testosterone is the enemy. He breaks down low testosterone is often linked to worse outcomes, androgen deprivation can accelerate decline, and emerging data suggests that carefully applied testosterone therapy may disrupt cancer progression while restoring quality of life.Dr. Stephen walks through the science behind bipolar androgen therapy, PSA misconceptions, and the real-world consequences of long-term hormone suppression. Helping men understand trade-offs, ask better questions, and make decisions based on lived experience rather than fear-driven protocols.Listen closely, reflect deeply, and decide how you want to live moving forward. Watch the episode of Prostate Cancer Didn't Kill Testosterone. Doctors Did.Enjoy the podcast? Subscribe and leave a 5-star review.Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: https://www.drstephenpetteruti.com/ Practice: www.intellectualmedicine.com YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: https://www.instagram.com/dr.stephenpetteruti/ Facebook: https://www.facebook.com/dr.stephenpetteruti    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com

We are in Week 2 of our 4-part series on Cancer, the #2 killer in America.  Dr. Prather talks about why Structure-Function Care and Disease Care must work together to get the best outcomes for patients.  In this episode, you'll find out:—How Holistic Integration's Structure-Function approach helps support patients going through Cancer treatments by keeping the body healthy and in homeostasis. —The story of the oncologist who called Dr. Prather about a terminal Prostate Cancer patient to ask what was being done to his patient because his PSA numbers were improving so dramatically. —The importance of Iodine for Breast Cancer and Fibrocystic Breasts  And how it has been shown to be effective for Prostate Cancer, Colorectal Cancer, and other types of Cancer as well. —Why Vitamin D is critical for Cancer and plays a huge role in our immune system.  And how Dr. Prather finds very few patients come in with proper Vitamin D levels.—The reason Dr. Prather refers to distilled water as "Cancer water".  And why you shouldn't drink too much alkaline water because Cancer cells are extremely alkaline.—The herbals that have anti-Cancer properties and are excellent for detoxification and for boosting the immune system. —Why an evaluation of nutritional deficiencies should be done to prevent and fight Cancer.  And why Anemia is something that should be taken seriously and can impact the survival rate from Cancer by 50%.—How Estrogen dominance can kick off Breast Cancer and Uterine Caner in Women.  And how almost all Prostate Cancers come from Estrogen dominance.—The astonishing story of the experiment Dr. Prater did as a student where rats who ate Wonder Bread "lost their hair, couldn't decide what sex they were, ate their young, and society just fell apart."—How Cancer patients who receive Acupuncture have 85% fewer symptoms and their fatigue levels are much les because "Acupuncture recharges the cells in the body".http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

In this episode of Moving Medicine Forward, we talk with Earnestine Walker and Ali Manson of ZERO Prostate Cancer about their mission to ensure every man—regardless of background—has access to early detection, support services, and quality care. They break down Blitz the Barriers, ZERO's major initiative targeting disparities in the hardest‑hit communities, and share how programs like ZERO360 and caregiver resources are transforming patient experiences.We also explore how policy advocacy, community partnerships, and patient voices are driving lasting change in prostate cancer outcomes nationwide. This is a powerful look at what equitable care truly requires—and how ZERO Prostate Cancer is helping move medicine forward. 00:00 – Welcome & IntroductionsMeet Earnestine Walker and Ali Manson of ZERO Prostate Cancer and hear about their roles leading patient programs, education, advocacy, and policy.01:00 – ZERO Prostate Cancer's MissionA look at how advocacy, education, awareness, and support guide every decision—and why “for all” is the organization's guiding star.02:00 – The Vision of Equitable CareDiscussion on what practical, equitable early detection and access look like in real communities.03:30 – Introducing Blitz the BarriersWhy ZERO launched its most ambitious initiative ever—and the staggering disparities it aims to confront.05:00 – The Cities Leading the Change A breakdown of the phased rollout across 12 high‑impact cities, from Baltimore to Appalachia.06:00 – Supporting Patients & FamiliesHow programs like ZERO360 and the Caregiver Retreats provide emotional, financial, and navigation support.08:00 – Navigating Financial BarriersThe role of patient navigation and how ZERO360 has delivered millions in financial assistance.09:30 – Advocacy in Action ZERO's long history on Capitol Hill and recent policy pushes to expand access to free prostate cancer screening.11:00 – Empowering Patient VoicesWhy patient stories and lived experiences are essential to driving legislative change.13:00 – Closing the Gap for Black Men & VeteransHow ZERO Prostate Cancer is addressing the needs of the communities most disproportionately impacted.15:00 – Measuring Impact & Expanding ReachWhat ZERO has achieved so far—and how new data strategies will track long‑term change.17:00 – The Power of Partnerships From national organizations to local community groups, how collaboration amplifies ZERO's equity‑driven mission.19:00 – What's Next for ZERO Prostate CancerA look at future goals, including the life-saving vision behind Blitz the Barriers through 2025.

In this podcast, the Brian, Tm and David Einstein discuss the EMBARK study and its implications for patients with biochemically relapsed prostate cancer. They explore the criteria for high-risk patients, the role of PSMA PET imaging, and the findings related to metastasis-free survival and overall survival. The conversation also delves into treatment strategies, adverse events, and patient perspectives on treatment decisions, ultimately highlighting the need for future research in this evolving field.

As men and their loved ones explore treatment options for prostate cancer, it's encouraging to know that ongoing innovation is shaping the management of this condition as technology advances. Today, we have the privilege of speaking with Dr. Mark Hong, a pioneer of an advanced treatment for men with prostate cancer and/or BPH, known as Transurethral Ultrasound Ablation, or TULSA. It is a minimally invasive MRI-guided procedure that destroys cancerous tissue while minimizing side effects. We're thrilled to partner with Profound Medical to introduce today's special guest. Dr. Hong is a board-certified urologist at Integrative Urology in Phoenix, Arizona, and a pioneer of MRI-guided TULSA-PRO incision-free surgery for prostate cancer. He completed his urology residency at Harvard Medical Center and earned selection as a national CAPTURE Scholar in prostate cancer. That allowed him to lead projects alongside world-leading scientists from the Dana-Farber Cancer Institute and the University of California, San Francisco. He also completed a fellowship in robotic and minimally invasive surgery at George Washington University in Washington, DC. He has published in almost every major international urology journal, having authored publications on topics ranging from prostate cancer detection to healthcare policy. Dr. Hong joins us today to share more about TULSA-PRO for men with prostate cancer. Having completed over 200 procedures, he has performed more TULSA procedures as an independent urologist, in the absence of a radiologist, than any other urologist in the world. Stay tuned for more! Disclaimer: The Prostate Health Podcast is for informational purposes only. Nothing in this podcast should be construed as medical advice. By listening to the podcast, no physician-patient relationship has been formed. For more information and counseling, you must contact your personal physician or urologist with questions about your unique situation. Show Highlights: Dr. Hong clarifies what the TULSA procedure is How the TULSA procedure differs from other technologies, in terms of its delivery, advantages, and outcomes Who are the ideal candidates for the TULSA procedure? The potential risks associated with the TULSA procedure What patients undergoing the TULSA procedure can expect How the development of new technologies leads to better outcomes for men with prostate cance Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd.  Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on Twitter and Instagram  Sign up for the Prostate Health Academy   You can access Dr. Pohlman's free mini-webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here. Podcast Partner: Profound Medical TULSA-PRO: https://tulsaprocedure.com/     

Coffee With Scott Adams Moves To The Scott Adams School~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~Chat With Scott Adams, Greg Gutfeld, Gus Gutfeld, Dr. Drew, Shelly Adams, Prostate Cancer's Survival Instinct, Minnesota Protest Theatrics, Iran Protests, Liberal White Women, Tyrus President Trump, Consciousness Concept, Dr. Hines, Owen Gregorian, AI Impacts Online Trust, Jack Posobiec, Two Movies One Screen, Scott Adams~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~If you would like to enjoy this same content plus bonus content from Scott Adams, including micro-lessons on lots of useful topics to build your talent stack, please see scottadams.locals.com for full access to that secret treasure.

In this Huberman Lab Essentials episode, my guest is Dr. Kyle Gillett, MD, a dual board-certified physician in family medicine and obesity medicine and an expert in optimizing hormone levels to improve overall health. We explain how to improve hormone levels across the lifespan in both men and women using behavioral, nutritional and exercise-based tools. We also discuss common clinical topics, including hormone testing, PCOS, hair loss, testosterone replacement therapy (TRT) and peptides, focusing on potential benefits, tradeoffs and risks. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Maui Nui: https://mauinuivenison.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Kyle Gillett (00:00:36) Hormone Health; Women vs Men, Tool: Hormone Testing (00:02:35) Tool: Big 6 Lifestyle Pillars to Optimize Hormone Health (00:04:32) Sponsor: AG1 (00:06:17) Diet, Individualization; Bloodwork & Frequency (00:07:20) Exercise, Zone 2 Cardio; Caloric Restriction (00:08:36) Intermittent Fasting, Growth Hormone, IGF-1 (00:11:05) Hormones & Sleep, Growth Hormone, Menopause, Andropause, TRT (00:13:28) Testosterone & Women, SHGB (00:15:19) Sponsor: Maui Nui (00:16:34) Dihydrotestosterone (DHT), Androgens; Turmeric & Black Pepper; Hair Loss (00:19:47) Polycystic Ovarian Syndrome (PCOS), Symptoms, Metformin, Inositol (00:23:13) Cannabis, Alcohol, Testosterone (00:24:48) Males & Testosterone, TRT, Prostate Cancer (00:26:04) Prolactin, Dopamine "Wave Pool", Tool: Casein & Gluten (00:27:23) Sponsor: Function (00:29:03) Social Relationships & Hormones, Tool: Planning for Crisis (00:31:02) Peptides, Growth Hormone & Risk; BPC 157, Sourcing & LPS (00:36:42) Melanotan, Uses & Risks (00:38:45) Spiritual Health, Interdisciplinary Health Integration (00:41:23) Caffeine & Hormones, Sleep; Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices